Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 4CNS 2Sarcoma 1Other solid neoplasm 1Other hematologic neoplasm 1Myeloid 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Wilms Tumor 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Medulloblastoma 1Lymphoma, Non-Hodgkin 1Histiocytosis, Langerhans-Cell 1Hepatoblastoma 1Glioma 1Ependymoma 1

Interventions

fludarabine 30Specimen Handling 28Cyclophosphamide 27Azacitidine 23venetoclax 22fludarabine phosphate 22Biopsy 22ruxolitinib 18Whole-Body Irradiation 17Cytarabine 17Mycophenolic Acid 16Busulfan 16asciminib 15Tacrolimus 15Melphalan 14Injections 12Decitabine 12decitabine and cedazuridine drug combination 11X-Rays 11Magnetic Resonance Spectroscopy 11Stem Cell Transplantation 10Granulocyte Colony-Stimulating Factor 10Sirolimus 9Peripheral Blood Stem Cell Transplantation 9Cyclosporine 9Thiotepa 8Filgrastim 8nilotinib 7Imatinib Mesylate 7Phantoms, Imaging 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pharmacogenomic Variants × Myeloid × 90 days × Clear all
NCT03698994 2026-05-27

Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
20 enrolled 9 charts
CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡